Results 81 to 90 of about 757 (146)

Additional file 1 of Effectiveness of azvudine in reducing mortality of COVID-19 patients: a systematic review and meta-analysis

Supplementary Material 1: Supplementary Table 1. Search strategy and original results from database. Supplementary Table 2. Risk of bias of included cohort studies. Supplementary Table 3.
Luo Wang (182514), Wangji Zhou (17377042), Siqi Pan (8506767), Hong Zhang (25820), Xinlun Tian (305900), Ying Zhang (40767), Huaiya Xie (17831291), Qiaoling Chen (419924), Aohua Wu (17831294), Junping Fan (9582035), Jinglan Wang (638536), Yaqi Wang (1555240), Xueqi Liu (12882488)   +12 more
core   +1 more source

Data_Sheet_1_Serial viral load analysis by DDPCR to evaluate FNC efficacy and safety in the treatment of mild cases of COVID-19.pdf

, 2023
IntroductionThe SARS-CoV-2 outbreak has threatened the human population globally as the numbers of reinfection cases even after large-scale vaccination.
Pingsheng Lei (5240192), Renato Martins da Silva (14787250), Paula Gebe Abreu Cabral (6515375), Antônio Brazil Viana Junior (14787268), Raul Ferraz Arruda (14787253), Sávio Bastos de Souza (6700298), Arícia Leone Evangelista Monteiro de Assis (14787259), Yolanda Porto Muniz Martins (14787262), Junbiao Chang (1523644), Sheila Passos de Figueiredo Cabral (14787256), Carlos Augusto de Araújo Tavares (14787265)   +10 more
core   +1 more source

DataSheet_1_Coinfection of SARS-CoV-2 and influenza A (H3N2) detected in bronchoalveolar lavage fluid of a patient with long COVID using metagenomic next−generation sequencing: a case report.pdf

, 2023
The growing number of long COVID cases has drawn clinical attention to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which has been spreading worldwide since winter 2019. Its symptoms are not limited to fatigue and shortness of breath but
Yajuan Zhang (838924), Xuefei Liang (16917174), Linlin Wang (289071), Qiushi Wang, Qiushi Wang (417314), Jia Liu (41593), Xuefei Liang, Jing Ma, Jing Ma (24574), Yajuan Zhang, Yang Yu, Yang Yu (4292), Meng Wang (124646), Linlin Wang, Jia Liu, Meng Wang   +15 more
core   +1 more source

Azvudine (FNC): a promising clinical candidate for COVID-19 treatment [PDF]

Signal Transduction and Targeted Therapy, 2020
Yu, Bin, Chang, Junbiao
openaire   +2 more sources

A Study on the Efficacy of Early Application of Azvudine in Viral Myocarditis under the Epidemic

Journal of Medicines Development Sciences
Objective: To explore the efficacy of early application of Azvudine in patients with viral myocarditis during the epidemic. Methods: Sixty patients diagnosed with "infection complicated with myocarditis" in our hospital from December 2022 to December 2023 were selected and randomly divided into an intervention group and a control ...
Minjie Wu, Linlin Tan, Anjian Yan
openaire   +1 more source

Efficacy of azvudine plus dexamethasone in severe hospitalized patients with Omicron infection: a prospective multicenter study [PDF]

BackgroundAzvudine (AZV), the first Chinese oral anti-coronavirus disease 2019 (COVID-19) drug, has shown substantial clinical benefits to viral clearance and prognosis in patients with mild and common COVID-19.
Meng-Lan Zhang, Nan Su, Xiao-Ying Wei, Guo-Peng Xu, Da-Xiong Zeng, Jung-Hong Jiang   +5 more
core   +1 more source

Masthead: (View 3/2025)

VIEW, Volume 6, Issue 3, June 2025.
wiley   +1 more source

Efficacy and Safety of Azvudine in Patients With COVID‐19 in China: A Meta‐Analysis of Observational Studies

The Clinical Respiratory Journal
ABSTRACTBackgroundAzvudine (FNC) is a novel small molecule antiviral drug for treating COVID‐19 that is available only on the Chinese market. Despite being recommended for treating COVID‐19 by the Chinese guidelines, its efficacy and safety are still unclear.
Tao Dong, Wentao Zhang, Tingting Wu, Yongxiang Ge, Qi Yang, Jia Xu, Yuna Liu   +6 more
openaire   +3 more sources

Antiviral effectiveness and survival correlation of azvudine and nirmatrelvir/ritonavir in elderly severe patients with COVID-19: a retrospective real-world studyResearch in context

EClinicalMedicine
Summary: Background: Azvudine and nirmatrelvir/ritonavir are approved to treat mild-to-moderate coronavirus disease 2019 (COVID-19) in adults with a high risk for progression to severe infection.
Shuxia Wang, Jin Sun, Xin Zhang, Man Li, Bangguo Qin, Miao Liu, Nan Zhang, Shengshu Wang, Tingyu Zhou, Wei Zhang, Cong Ma, Xinli Deng, Yongyi Bai, Geping Qu, Lin Liu, Hui Shi, Bo Zhou, Ke Li, Bo Yang, Suxia Li, Fan Wang, Jinling Ma, Lu Zhang, Yajuan Wang, Li An, Wenhui Liu, Qing Chang, Ru Zhang, Xi Yin, Yang Yang, Qiangguo Ao, Qiang Ma, Shuangtong Yan, Haili Huang, Peng Song, Linggen Gao, Wenning Lu, Lining Xu, Li Lei, Keyu Wang, Qi Zhang, Qing Song, Zhijian Zhang, Xiangqun Fang, Yao He, Tianzhi Li, Ping Zhu   +46 more
doaj   +1 more source

Selectively T cell phosphorylation activation of azvudine in the thymus tissue with immune protection effect

Acta Pharmaceutica Sinica B
Thymus is the important immune organ, responsible for T cell development and differentiation. The lower circulating T counts have been observed in patients who died from COVID-19 compared with survivors. Azvudine, also known as FNC, is a thymus-homing anti-SARS-CoV-2 drug in treating COVID-19 patients.
Ning Sheng, Rui Li, Yang Li, Zhe Wang, Lulu Wang, Yuhuan Li, Jinlan Zhang, Jiandong Jiang   +7 more
openaire   +3 more sources